MedPath

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Phase 3
Terminated
Conditions
Benign Prostatic Hyperplasia
Enlarged Prostate
Registration Number
NCT00435448
Lead Sponsor
Threshold Pharmaceuticals
Brief Summary

The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
480
Inclusion Criteria
  • Capable of understanding the purpose and risks of the study and sign a statement of informed consent
  • Male 50-80 years of age
  • Presence of LUTS (lower urinary tract symptoms) for at least 3 months
  • Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc
  • Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)
  • I-PSS (International prostate symptom score) > 12
  • PSA > 1.0 ng/mL
  • Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential
  • Able to comply with the prescribed treatment protocol and evaluations
Exclusion Criteria
  • Prior treatment for BPH with alpha-blockers and/or herbal supplements in the past 2 weeks (alpha-blockers and herbal supplements for the treatment of BPH are not allowed during the study). Prior treatment with 5-alpha-reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.

  • Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)

  • Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (for subjects with PSA between 4 - 10 ng/mL, prostate cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA >10 ng/mL are excluded.)

  • Active urinary tract infections (UTI)

  • Active cardiac, renal or hepatic disease as evidenced by:

    1. Serum creatinine > 1.8 mg/dL
    2. ALT or AST > 2.5x the upper limit of normal at screen
    3. History of active myocardial infarction,unstable cardiac arrhythmias or stroke within 6 months prior to screening
    4. Uncontrolled congestive heart failure
  • Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)

  • Use of systemic teriods for any reason (systemic steroid usage is not allowed during the study). Inhaled and/or topical steroids are allowed.

  • Concurrent participation or participation in an investigational drug study within the past 30 days prior to screening

  • Concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the investigator,pose an unnaceptabele risk to the subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
International prostate symptom score (I-PSS)
Secondary Outcome Measures
NameTimeMethod
Qmax on uroflowmetry
Post micturitional residue
Volume of the prostate
PSA

Trial Locations

Locations (58)

Wojewódzki Szpital,Oddział i Poradnia Urologiczna

🇵🇱

Legnica, Poland

Dombóvári Szt. Lukács Egészségügyi Közhasznú

🇭🇺

Dombóvár, Hungary

Petz Aladár County Hospital

🇭🇺

Gyor, Hungary

Semmelweis University

🇭🇺

Budapest, Hungary

Fővárosi Önkormányzat Jahn Ferenc Dél-Pesti Kórház

🇭🇺

Budapest, Hungary

Kaposi Mór County Hospital

🇭🇺

Kaposvar, Hungary

Nagykanizsa Megyei Jogú Város Hospital

🇭🇺

Nagykanizsa, Hungary

Gróf Esterházy Kórház

🇭🇺

Papa, Hungary

Dr. Bugyi István Hospital

🇭🇺

Szentes, Hungary

Saint Bobála Hospital

🇭🇺

Tatabánya, Hungary

Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka, Oddział Urologii

🇵🇱

Slupsk, Poland

Szpital Specjalistyczny, Oddział Urologii

🇵🇱

Wejherowo, Poland

Urologische Klinik und Poliklinik der Technischen Universität München, Klinikum Rechts der Isar

🇩🇪

München, Germany

Károlyi Sándor Hospital

🇭🇺

Budapest, Hungary

Universitätsklinik Köln, Klinik und Poliklinik für Urologie

🇩🇪

Köln, Germany

ClinPharm International GmbH & Co KG--Dresden

🇩🇪

Dresden, Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Urologie und Kinderurologie

🇩🇪

Kiel, Germany

ClinPharm International GmbH & Co KG--Magdeburg

🇩🇪

Magdeburg, Germany

Ospedale S.Annunziata, Unità Operativa di Urologia

🇮🇹

Firenze, Italy

Urologische Universitätsklinik, Klinikum Mannheim gGmbH, Fakultät für Klinische Medizin Mannheim

🇩🇪

Mannheim, Germany

Klinikum der Universität München, Urologische Klinik und Poliklinik

🇩🇪

München, Germany

Klinik für Urologie und Kinderurologie, Klinikum Marburg

🇩🇪

Marburg, Germany

ClinPharm International GmbH & Co KG--Chemnitz

🇩🇪

Chemnitz, Germany

Gemeinschaftspraxis Jacobi - Hellmis

🇩🇪

Duisburg, Germany

ClinPharm International GmbH & Co KG--Leipzig

🇩🇪

Leipzig, Germany

A.O. Policlinico di Bari, Clinica Urologica

🇮🇹

Bari, Italy

Azienda Ospedaliera, Dipartimento di Urologia

🇮🇹

Padova, Italy

ClinPharm International GmbH & Co KG--Frankfurt/Main

🇩🇪

Frankfurt, Germany

Klinik für Urologie, Eberhard-Karls-Universität Tübingen

🇩🇪

Tubingen, Germany

Vivantes Klinikum am Urban, Klinik für Urologie

🇩🇪

Berlin, Germany

Clinic of Urology

🇭🇺

Debrecen, Hungary

Wuppertaler Gemeinschaftspraxis für Dermatologie, Gynäkologie und Urologie

🇩🇪

Wuppertal, Germany

Wojewódzki Szpital Specjalistyczny nr 4

🇵🇱

Bytom, Poland

"Specjalista" Spółka z o. o.

🇵🇱

Kutno, Poland

Szpital Specjalistyczny Oddzial Urologii

🇵🇱

Koscierzyna, Poland

Specjalistyczna Praktyka Lekarska

🇵🇱

Katowice, Poland

Katedra i Klinika Urologii Pomorskiej Akademii Medycznej

🇵🇱

Szczecin, Poland

Katedra i Klinika Urologii AM we Wrocławiu

🇵🇱

Wroclaw, Poland

A.O. Policlinico di Bari, Clinica Urologica I

🇮🇹

Bari, Italy

Università di Genova Ospedale S. Martino, Reparto Urologia

🇮🇹

Genova, Italy

Azienda Ospedaliera S.Luigi di Orbassano, Reparto di urologia universitaria

🇮🇹

Orbassano, Italy

A.O. Pliclinico Paolo Giaccone, U.O. Urologia con Litotrissia Extracorporea

🇮🇹

Palermo, Italy

Azienda Ospedaliera Pisana, Dipartimento di Urologia 1

🇮🇹

Pisa, Italy

Ospedale Maggiore S.Giovanni Battista, Istituto di Urologia

🇮🇹

Torino, Italy

Urologische Klinik, Klinikum Landkreis Neumarkt i.d.Obf.

🇩🇪

Neumarkt, Germany

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie

🇩🇪

Hamburg, Germany

niversitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Urologie

🇩🇪

Dresden, Germany

ClinPharm International GmbH & Co KG--Gorlitz

🇩🇪

Gorlitz, Germany

Policlinico Sassarese, Istituto di Clinica Urologica

🇮🇹

Sassari, Italy

Klinika Urologii AM w Białymstoku

🇵🇱

Bialystok, Poland

Ospedale S.Paolo, Cattedra di Urologia

🇮🇹

Milano, Italy

Università Federico II, Clinica Urologica Edificio 5

🇮🇹

Napoli, Italy

Ospedale S.Giovanni Bosco, Dipartimento di Urologia

🇮🇹

Torino, Italy

Gabinet Urologiczny

🇵🇱

Gdańsk, Poland

Szpital Im. Kardynała Stefana Wyszyńskiego, Oddział Urologii

🇵🇱

Lublin, Poland

Szpital Bielański, Oddział Urologii

🇵🇱

Warszawa, Poland

NZOZ Lekarze Urolodzy, Marek Rozniecki i Partnerzy

🇵🇱

Łask, Poland

Katedra i Klinika Urologii Śląskiej Akademii Medycznej

🇵🇱

Zabrze, Poland

© Copyright 2025. All Rights Reserved by MedPath